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Objectives:  To  determine  the  usefulness  of  myeloperoxidase  in  discriminating  between  patients
with acute  coronary  syndrome  and  patients  with  chest  pain  by  other  causes.
Methods:  The  study  included  all  patients  over  18  years  of  age  who  come  consecutively  to
the emergency  department  from  September  2015  to  December  2015  with  chest  pain  of  non-
traumatic  origin.  The  initial  patient  evaluation  was  performed  according  to  the  study  protocol
for patients  with  suspected  acute  coronary  syndrome  (ACS)  in  our  Emergency  Department.
This included  the  serial  measurement  of  troponin,  and  in  this  case  myeloperoxidase,  with
serialization  on  admission  and  at 6  h.
For the  determination  of  myeloperoxidase  (MPO),  a  single  step  sandwich  enzyme  immunoas-
say by  Siemens,  automated  on  a  Dimension  analyser,  was  used.
Results:  Statistically  significant  differences  were  observed  in  the  concentration  of  myeloper-
oxidase  at  time  0 among  patients  diagnosed  with  ACS:  505  (413)  pmol/L,  and  non-ACS  patients:
388 (195)  pmol/L  (p  <  .001),  as  well  as at  6  h  (p  < .001).
An area  under  the  curve  ROC  of  0.824  was  obtained  at 6  h  for  ACS  patients,  with  a  confidence
interval  of  95%  from  0.715  to  0.933  and  a  level  of  significance  of  p  <.001.
Statistically  significant  differences  were  also  found  in  the  concentration  of  myeloperoxidase
at time  0  and  at 6 h  among  patients  with  ACS  and  patients  with  heart  disease  other  than  coronary
artery  disease.
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Conclusions:  The  concentration  of  MPO  helps  to  differentiate  between  ACS  and  non-ACS
patients,  as well  as between  ACS  patients  and  patients  with  heart  diseases  other  than  coronary
artery  disease.
©  2017  Instituto  Nacional  de  Cardioloǵıa Ignacio  Chávez.  Published  by  Masson  Doyma  México







Servicio  de  urgencias;
Dolor  torácico;
España
Utilidad  de  la  determinación  de  mieloperoxidasa  en  el  diagnóstico  diferencial  del
síndrome  coronario  agudo
Resumen
Objetivos:  Conocer  la  utilidad  de  mieloperoxidasa  (MPO)  para  discriminar  entre  pacientes  con
síndrome  coronario  agudo  y  dolor  torácico  de  otras  causas.
Métodos:  De  septiembre  a  diciembre  de  2015  se  incluyeron  todos  los  pacientes  mayores  de  18
años que  acudieron  de  forma  consecutiva  al  servicio  de  urgencias  con  dolor  torácico  de  origen
no traumático.  La  evaluación  inicial  del  paciente  se  realizó  de  acuerdo  con  el protocolo  de
estudio para  pacientes  con  sospecha  de  síndrome  coronario  agudo  (SCA)  en  nuestro  servicio  de
urgencias,  que  incluye  la  medición  de  troponina  y  en  este  caso  MPO,  con  serialización  al  ingreso
y a  las  6  h.
Para  la  determinación  de  MPO  se  utilizó  un inmunoensayo  enzimático  de  tipo  sándwich,  de
una sola  etapa  de  Siemens,  automatizado  en  un equipo  Dimension
®
.
Resultados:  Se obtuvieron  diferencias  estadísticamente  significativas  en  la  concentración  de
MPO a  tiempo  0 entre  los  pacientes  con  diagnóstico  de  SCA:  505  (413)  pmol/l  y  los  pacientes  no
SCA:  388  (195  pmol/l  (p  < 0.001),  así  como  a  las  6 h  (p  <  0.001).
Se obtuvo  a  las  6 h un  área  bajo  la  curva  ROC  para  pacientes  con  SCA  de  0.824  con  un  intervalo
de confianza  del  95%  de  0.715  a  0.933  y  un  grado  de  significación  p  < 0.001.
También  se  obtuvieron  diferencias  estadísticamente  significativas  en  la  concentración  de  MPO
tanto a  tiempo  0 como  a  las  6 h  entre  pacientes  con  SCA  y  pacientes  con  enfermedad  cardiaca
diferente  de  enfermedad  coronaria.
Conclusiones:  La  concentración  de  MPO  sirve  para  diferenciar  entre  pacientes  SCA y  pacientes
que no  son  SCA,  así  como  entre  pacientes  SCA  y  pacientes  con  otras  enfermedades  cardiacas
diferentes  a la  enfermedad  coronaria.
©  2017  Instituto  Nacional  de  Cardioloǵıa Ignacio  Chávez. Publicado  por  Masson  Doyma  México
S.A. Este  es  un  art́ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Introduction
Cardiovascular  disease  is  the  leading  cause  of  death  in
developed  countries  and  it  is  expected  to  be  in  2020  the
first  cause  of death  in  developing  countries.  On  the  other
hand,  acute  chest  pain  of  possible  coronary  origin  is  one
of  the  most  frequent  causes  of  consultation  in  emergency
services.
Early  diagnosis  of  acute  coronary  syndrome  (ACS)  is
frequently  a  challenging  task,  while  immediate  risk  strat-
ification  remains  crucial  for  the  prompt  implementation  of
appropriate  therapy  in  this  setting.
However,  the  prolonged  release  pattern  of troponins,
well  established  biomarkers  of  myocardial  necrosis,  and
limited  sensitivity  of  the  routine  troponin  assay  make  it
difficult  to  diagnose  ACS  at  an  early  stage.
The  ACS  is  usually  caused  by  the  rupture  of  a  coro-
nary  plaque  producing  a  sudden  and  critical  reduction  in
blood  flow  and  includes  various  clinical  manifestations  ran-
ging  from  Acute  Myocardial  Infarction  (AMI)  with  ST-segment
elevation  and  myocardial  infarction  without  elevation  of  ST
segment  to  unstable  angina.
Myeloperoxidase  (MPO)  is  an  enzyme  released  by  the  acti-
vation  and  degranulation  of  polymorphonuclear  cells  and
monocytes  that  is  involved  in  the  production  of  free  radicals,
responsible  for  the  LDL  cholesterol  oxidation.  The  oxida-
tive  modification  of  LDL  leads  to  the  increase  of  its  uptake
and  degradation  by  macrophages,  resulting  in  cholesterol
deposit  and  formation  of foam  cells,  the  cellular  mark  of
the  fatty  streaks.
It is  also  involved  in  the  activation  of  metalloproteinases
and  in  the  instability  and  plaque  rupture1,2 as  well  as  in
the  bioavailability  of  nitric  oxide,  derived  of endothelium,
thereby  altering  the  tone  and  certain  anti-inflammatory
properties  of  the  endothelium.
Some  studies  show  that  the  concentration  of  MPO  is
higher  in  ACS  patients3,4 thus,  it  has  been  proposed  as  a
useful  risk  marker  and  diagnostic  tool  in  ACS  and  in  patients
admitted  to  the  emergency  department  for  chest  pain.5
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Also,  whereas  troponin  T  takes  3--6  h  to  rise  following
chest  pain,  MPO  levels  already  rise  even  within  2 h after  the
onset  of  symptoms.
But,  although  it  seems  that  myeloperoxidase  can  inde-
pendently  predict  the  onset  of  coronary  artery  disease,6
there  are  few  studies  comparing  the  value  of  the  determi-
nation  of  myeloperoxidase  and  other  cytokines  that  reflect
endothelial  activity  among  patients  with  acute  coronary  syn-
drome  and  patients  with  stable  angina  or  other  causes  of
non-traumatic  chest  pain.7
Material and methods
From  September  2015  to  December  2015  we  included  all
patients  over  18  years  of  age  who  come  consecutively  to
the  emergency  department  with  chest  pain  of non-traumatic
origin.  Exclusion  criteria  were:  age  less  than  18 years,  active
cancer,  pulmonary  embolism,  cerebral  infarction  or  periph-
eral  vascular  disease  as  well  as  chronic  advanced  diseases
such  as  cirrhosis  and  heart  or  kidney  failure,  communica-
tion  difficulties,  cognitive  impairment,  acute  infections  or
inflammatory  states.  The  study  design  was  transversal  ana-
lytical.
Patients  who  came  to  the  emergency  department  12  h
after  the  onset  of  chest  pain  were  also  excluded,  since  in
these  patients  is  not  necessary  Troponin  serial  determina-
tions,  as  well  as  patients  whose  first  Troponin  was  positive,
because  in  these  cases  the  diagnosis  of  Acute  Myocardial
Infarction  (AMI)  is  already  firmly  established.
In each  patient  who  participated  it  was  obtained  infor-
mation  on  epidemiological  data  such  as  age,  sex  and
risk  factors  for  cardiovascular  disease  such  hypertension
(blood  pressure  ≥ 140/90  mmHg  or  treatment  with  antihy-
pertensive  drugs),  diabetes  mellitus,  dyslipidemia  (when  the
patient  is  taking  lipid-lowering  drugs),  smoking,  family  his-
tory  in  first  degree  of ischemic  heart  disease  and  obesity
(BMI  >  30  kg/m2).
In  each  patient  who  participated,  informed  consent  was
obtained.
The  initial  patient  evaluation  was  performed  according
to  the  study  protocol  patient  with  suspected  ACS  in  our
emergency  department,  which  includes  the  measurement  of
troponin  and  in  this  case  myeloperoxidase  with  serialization
on  admission  and  at  6  h.
After  15  min  of resting  20  ml  of  blood  was  extracted,
10  ml  in  a  EDTA  container  for  the  determination  of  myeloper-
oxidase  and  10  ml  in  a  tube  without  additives,  only  with  gel
separator  for  determination  of serum  parameters.
In our  study  MPO  was  measured  in  plasma  EDTA  sam-
ples  and  the  plasma  was  quickly  separated  and  frozen  at
-80 ◦C until  determination  of  myeloperoxidase.  The  pre-
ferred  sample  for  determination  of  MPO  is  plasma  with  EDTA,
since  serum  or  heparin  plasma  gave  consistently  higher  val-
ues  due  to  MPO  leakage  from  leucocytes.8
For  the  determination  of  myeloperoxidase  a  single  step
sandwich  enzyme  immunoassay  of  Siemens,  automated  in
Dimension  equipment,  was  used.
The  measurement  interval  of myeloperoxidase  is
between  20  and  5000  pmol/L  and  its detection  limit
is  13  pmol/L.
For  a level  of  myeloperoxidase  of  ≤20  pmol/L  a  variation
coefficient  of 20%  is  obtained.
According  to  the  manufacturer  the  detection  limit  for  this
technique  is  1.5  pg/ml  and  shows  no cross  reactivity  with
IL-1alpha,  IL-1beta,  IL-2,  IL-3,  IL-4,  IL-8  and  alpha  TNF.
Statistical analysis of the data
Continuous  variables  are  expressed  as  mean  ±  standard  devi-
ation  or  median  (interquartile  range)  according  to  their
distribution,  and  qualitative  variables  as  frequencies.  For
comparison  of qualitative  variables  the  test  of  Chi  Squared
was  used  and  for  comparison  of  quantitative  variables  the
nonparametric  Mann--Whitney  test  was  used.  For  multi-
ple  comparisons  the  Bonferroni  method  was  used.  It is
considered  significant  a  value  of  p  <  0.05.  Myeloperoxidase
diagnostic  performance  is  calculated  by  analyzing  the  area
under  the  Receiver  Operating  Characteristic  (ROC)  curve
with  a confidence  interval  of  95%  (95%  CI).
For  statistical  analysis  of the  data  the  SPSS  version  20.0
(IBM,  USA)  has  been  used.
Results
During  the  study  period,  83  patients  were  included.  The
average  age  of  them  was  68  ±  15  years  and  52%  were  male.
NSTEMI  were  diagnosed  in  15.7%  of all  patients  and  19.3%  of
they  had  unstable  angina.  13.2%  were  diagnosed  with  stable
angina.  20.5%  of patients  had  heart  disease  different  of  ACS
and  31.3%  of  them  were  diagnosed  with  chest  pain  of  non-
coronary  origin.  The  classification  of  patients  was  done  as
follows:
Stable  angina  was  diagnosed  as  chest  pain  typical  of cardiac
ischemia  on  exertion.9
Unstable  angina  was  diagnosed  in  patients,  who  had  new-
onset  angina  within  2  months  after  a previous  bout;
angina  with  a  progressive  crescendo  pattern  or  with  the
angina  episodes  increasing  in  frequency  and/or  duration;
or  angina  that  occurred  at  rest.10
NSTEMI.  Patients  with  persistent  or  transient  ST-segment
depression,  inversion  or  pseudo-normalization  of  T-waves
during  symptoms  and  subsequent  normalization.
ACS  patients.  It includes  patients  with  unstable  angina  and
NSTEMI  patients.
Patients  with  heart  disease  different  to  cardiac  coronary
disease  (CAD).  When  CAD  was  excluded  by  additional  test-
ing.
Non-cardiac  chest  pain.  When  a cardiac  etiology  was
excluded.
Table  1  shows  the  general  characteristics  of  the  patient
sample  studied  as  well  as  those  of the  ACS  and  non-ACS
patients.
No  statistically  significant  differences  were  found
between  ACS  and  non-ACS  patients  in  age,  gender,  and  car-
diovascular  risk  factors  except  for  hypertension.
There  are  a  greater  proportion  of hypertensive  patients
in  the  group  of patients  with  ACS  (p  <  0.01)  (Table  1).
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Table  1  General  characteristics  of  the  sample  of  patients  studied.
Variable  General  population  n  =  83  ACS  patients  Non-ACS  patients  p
Males  n  (%)  52  (62.7)  20  (68.96)  32  (59.26)  0.383
Age in  years  73  (23)  74  (18)  69  (23)  0.123
Myeloperoxidase  t0  432  (264)  505  (413)  388  (195)  <0.001
Myeloperoxidase  t6  410  (280)  550  (599)  316  (175)  <0.001
Cardiovascular  risk  factors  n  (%)
Hypertension  n  (%)  46  (55.42)  21  (72.4)  25  (46.39)  <0.01
IDDM n  (%)  6 (7.23)  3  (10.34)  3  (5.55)  0.382
NIDDM n  (%) 16  (19.28)  7  (24.13)  9  (16.66)  0.346
Dislypemia  n  (%) 29  (34.94) 13  (44.82)  16  (27.77)  0.081
Hypothyroidism  n  (%) 4  (4.82) 1  (3.44) 3  (5.55) 0.705
Obesity n  (%) 5  (6.02) 1  (3.44) 4  (7.41) 0.503
Smoking (yes)  n (%)  14  (16.81)  6  (20.69)  8  (11.11)  0.546
ACS, acute coronary syndrome; IDDM, insulin dependent diabetes mellitus; NIDDM, non-insulin dependent diabetes mellitus.
This  shows  that  the  differences  in  MPO  concentration
between  the  two  groups  are  not  influenced  by these  poten-
tially  confounding  variables.
No  statistically  significant  differences  between
the  concentration  of  myeloperoxidase  at  time  0:  432
(264)  pmol/L  and  at  6  h:  410  (280)  pmol/L  were  obtained  in
the  total  group  of patients  (p  =  0.812).  We  obtained
statistically  significant  differences  in  the  values  of
myeloperoxidase  at  time  0  among  patients  diagnosed
with  ACS  (NSTEMI  patients  and  unstable  angina  patients):
505  (413)  pmol/L  and  non-ACS  patients:  388  (195)  pmol/L
(p  <  0.001)  as  well  as  at  6 h:  550  (599)  pmol/L  in  patients
ACS  vs.  316  (175)  pmol/L  in  non-ACS  patients  (p  < 0.001).
The  analysis  of  the  area  under  the  curve  Receiver  Oper-
ating  Characteristics  (ROC)  for  myeloperoxidase  in  the  SCA
patients  at  time  0 was  of  0.755  with  a  confidence  inter-
val  of  95%  from  0.644  to  0.866  and  a  degree  of  significance
p  < 0.001.  For  the  time  6  we  obtained  an  area  under  the
curve  of  0.824  with  a confidence  interval  of  95%  from  0.715
to  0.933  and  a degree  of significance  p <  0.001  (Fig.  1).
When  we refer  to  differences  in  the  concentration  of
myeloperoxidase  among  different  groups  according  to  their
pathology,  we can  appreciate  the  following:
• We  find  statistically  significant  differences  in  the  concen-
tration  of  myeloperoxidase  when  comparing  the  group  of
patients  ACS  with  the  patients  with  chest  pain  of non-
coronary  origin,  at  time  0:  505  (413)  pmol/L  vs.  345.5
(215)  pmol/L  (p  <  0.01)  as well  as  at  6 h:  550  (599)  pmol/L
vs.  249  (237)  pmol/L  (p  < 0.05)  (Fig.  2).
•  It  was  also  obtained  statistically  significant  differences
in  the  concentration  of  myeloperoxidase  at  time  0
among  patients  with  ACS:  505  (413)  pmol/L  and  patients
with  heart  disease  different  of coronary  artery  disease
(CAD),  392  (119.5)  pmol/L  (p  <  0.05)  as  well  at  6  h: 550
(599)  pmol/L  vs.  318  (90)  pmol/L  (p  <  0.05)  (Fig.  2).
•  Also,  we  obtained  statistically  significant  differences
when  we  compare  the  concentrations  of  myeloperoxidase
in  patients  with  ACS  with  those  with  stable  angina  at  6 h:
550  (599)  pmol/L  vs.  345  (242)  pmol/L  (p  < 0.05)  (Fig.  2)
and  at  0  h the  differences  did  not  reach  statistical  signifi-
cance:  505  (413)  pmol/L  vs.  396  (346)  pmol/L  (p  =  0.098).
AUC = 0.824



















Figure  1 Analysis  of  the  area  under  the  ROC  curve  for
myeloperoxidase  at  6  h  in  the  group  of  acute  coronary  syndrome
patients.
AUC = area  under  the  ROC  curve.  CI  =  confidence  interval.
Discussion
Zhang  et al.11 were  the  first  to  describe  the  correlation
between  serum  MPO  levels,  leukocyte  MPO  levels  and  the
presence  of coronary  artery  disease.
In  our  study  significant  increases  in  MPO  levels  were
observed  in  acute  coronary  syndrome  patients  compared  to
patients  without  ACS  (p  <  0.001).
It confirms  earlier  reports  indicating  markedly  elevated
plasma  concentrations  of  MPO  within  2 h  of  symptoms  onset
in  patients  with  myocardial  infarction12 or  in  patients  with
ACS  presenting  within  3--12  h  of  their  last  episode  of  chest
pain.13
MPO  is  linked  to  both  inflammation  and  oxidative  stress
by  its location  in  leukocytes  and  its  role  in  catalyzing  the


























Figure  2  Myeloperoxidase  concentration  at  6  h  among  different  groups  of  patients  according  to  their  pathology.
*Patients  with  acute  coronary  syndrome  (patients  with  non-ST  segment  elevation  myocardial  infarction  (NSTEMI)  + patients  with
unstable angina).
formation  of oxidizing  agents.  It seems  to  contribute  directly
to  the  pathogenesis  of  ACS.  Oxidative  stress  participates  in
all  stages  of cardiovascular  disease,  from  lipoprotein  modifi-
cation  to  plaque  rupture,  and  biomarkers  of oxidative  stress
predict  development  of  coronary  artery  disease  (CAD).14
Several  lines  of  evidence  strongly  suggest  also  the  exist-
ence  of  a link  between  MPO  and  CAD.  Genetic  studies  of
subjects  with  either  total  or  subtotal  MPO  deficiency15 or  of
subjects  with  reduced  expression  of  MPO  due  to  a promoter
polymorphism16,17 seem  to  be  less  likely  to  develop  CAD
or  its  clinical  manifestations  such  as  non-fatal  myocardial
infarction  or  cardiac  death.
Elevated  MPO  in  our  study  was  associated  with  the  pres-
ence  of  acute  coronary  syndrome  with  an  area  under  ROC
curve  of  0.755  (CI  0.644--0.866;  p < 0.001)  at  time  0  and  even
better  values  of  the  area  under  the  curve  ROC  at  6 h  0.824
(CI  0.715--933;  p < 0.001).
Our  results  show  that  the  concentration  of  myeloperox-
idase  at  6  h  allows  us  to  discriminate  better  between  ACS
and  non-ACS  patients  (best  area  under  the  ROC  curve)  and
between  ACS  patients  and  patients  with  stable  angina.
Like  Samsamshariat  et al.18 we  find  plasma  MPO  levels
higher  at  time  0 in  SCA  patients:  505  (413)  pmol/L  than  in
patients  with  stable  angina  396  (346)  pmol/L  and  muscular
pain  patients  345.5  (215)  pmol/L  as  well  as  at  6  h.
MPO  progressively  increases  with  the  increase  in  clinical
severity  of  CAD  from  stable  CAD  to  non-ST  segment  elevation
acute  coronary  syndrome.
The  higher  concentration  of  MPO  found  in  unstable  CAD
patients  as  compared  with  stable  CAD  patients  may  be
related  to  plaque  instability  and  neutrophil  activation  that
have  been  demonstrated  by  some  studies.19,20
This  also  highlights  that  the  elevation  of  MPO  can  facili-
tate  the  diagnosis  of ACS,  having  a  greater  interest  in  acute
conditions,  such  as  NSTEMI  or  unstable  CAD.
Another  important  conclusion  of  our  study  is  that  the
concentration  of  both  MPO  at  0 h  and  at  6  h  allows  differ-
entiation  between  SCA  patients  and  patients  with  any  heart
disease  different  from  coronary  artery  disease,  results  that
agree  with  those  obtained  by  Sawicki  et  al.21
However,  in  a recent  report  Eggers  et al.22 argued  that
MPO  provides  no  clinically  relevant  information  in  unse-
lected  patients  with  chest  pain  presenting  within  8 h.
They  use  also  a  fully  automated  chemiluminescent
microparticle  immunoassay  but  do  not  find  significant  dif-
ferences  in  median  MPO  concentrations  between  patients
with  unstable  angina  or  myocardial  infarction  and  those
other  with  heart  disease  or  non-cardiac  disease  were
found.
Our  study  was  performed  like  as  the  study  performed
by  Sawicki  et al.21 in  one  emergency  department,  whereas
the  study  of  Eggers  et al.22 was  performed  in  three  dif-
ferent  medical  centers,  which  might  have  influenced  the
selection  of  chest  pain  patients.  On  the  other  hand,  sev-
eral  recent  clinical  studies  have  shown  that  elevated  MPO
level  correlates  with  angiographic  severity  of  CAD  and
predicts  adverse  events  in  patients  with  acute  coronary
syndromes.23--25
In the  study  by  Baldus  et  al.,13 myeloperoxidase  remained
an  independent  and  powerful  predictor  of  cardiac  risk  at
both  30  days  and  follow-up.
In conclusion,  although  we  have  a  small  number  of
patients  (n  =  83)  we  can  say  that  myeloperoxidase  clari-
fies  the  pathophysiology  of ACS  and  also  enables  a better
396  P.  Calmarza  et  al.
understanding  of  ACS  helping  the  physician  to  differentiate
between  ACS  patients  and  non-ACS  patients.
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